AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31964398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-independent prescribing service (PIP) for 6 months
Number of subjects: 880
Study 31964398 — intervention group
Group type: COMPARATOR
Intervention: Usual general practitioner (GP)-led care
Number of subjects: 880
Study 30287210 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 909
Study 30287210 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks (Q2W)
Number of subjects: 909
Study 30287210 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (initially uptitrated)
Number of subjects: 909
Study 30287210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 909
Study 26766119 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute experimental stress (impending Trier Social Stress Task)
Number of subjects: 40
Study 26766119 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 40
Study 24970570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostomy formation with mesh
Number of subjects: 240
Study 24970570 — intervention group
Group type: COMPARATOR
Intervention: Colostomy formation without mesh (two types)
Number of subjects: 240
Study 24970570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostomy formation (all types)
Number of subjects: 240
Study 22284340 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant micronutrients and glutamine supplementation
Number of subjects: 20
Study 22284340 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isoenergetic amounts of maltodextrine)
Number of subjects: 20
Study 20682881 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine, 50 mg capsule taken orally three times per day for 28 days
Number of subjects: 288
Study 20682881 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate, 20 mg/kg body weight per day for 20 days by intramuscular injection
Number of subjects: 288
Study 19080711 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy group
Number of subjects: 90
Study 19080711 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy group
Number of subjects: 90
Study 19080711 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation alone group
Number of subjects: 90
Study 19080711 — intervention group
Group type: COMPARATOR
Intervention: All groups (7 days after operation)
Number of subjects: 90
Study 19080711 — intervention group
Group type: COMPARATOR
Intervention: All groups (1 month after operation)
Number of subjects: 90
Study 16882108 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Pioglitazone
Number of subjects: 0
Study 16882108 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Rosiglitazone
Number of subjects: 0
Study 12810423 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement feedback system
Number of subjects: 264
Study 12810423 — intervention group
Group type: COMPARATOR
Intervention: Control period (no feedback)
Number of subjects: 264
Study 10591283 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management (titration followed by monthly visits)
Number of subjects: 579
Study 10591283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral treatment (parent, school, and child components)
Number of subjects: 579
Study 10591283 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (medication management + intensive behavioral treatment)
Number of subjects: 579
Study 10591283 — intervention group
Group type: COMPARATOR
Intervention: Standard community care (treatments by community providers)
Number of subjects: 579
Study 8693597 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with two courses of cisplatin (120 mg/m2 i.v. day one) plus bleomycin (20 mg/m2/day for 5 consecutive days in 24-hr i.v. perfusion) followed by definitive surgery and postoperative radiation therapy
Number of subjects: 96
Study 8693597 — intervention group
Group type: COMPARATOR
Intervention: Surgery plus postoperative radiation therapy (50-60 Gy)
Number of subjects: 96
Study 1819631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% Cx
Number of subjects: 44
Study 1819631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% NaF
Number of subjects: 44
Study 1819631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% Cx plus 0.2% NaF
Number of subjects: 44
Study 1819631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 6110956 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-donor platelet transfusions
Number of subjects: 34
Study 6110956 — intervention group
Group type: COMPARATOR
Intervention: Multiple-donor platelet transfusions
Number of subjects: 34
Study 31537219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (after 72 hours of treatment at 32-35 centigrade, increasing about 1 centigrade every 6 hours until normal temperature)
Number of subjects: 60
Study 31537219 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (lowering intracranial pressure, anticoagulation, improving microcirculation, neurotrophy and anti-stress ulcer)
Number of subjects: 60
Study 30161205 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 96
Study 30161205 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir + Ritonavir (ATV/r)
Number of subjects: 96
Study 30161205 — intervention group
Group type: COMPARATOR
Intervention: Darunavir + Ritonavir (DRV/r)
Number of subjects: 96
Study 26794168 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider training intervention at clinics (4-hour training)
Number of subjects: 1500
Study 26794168 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid family planning expansion programs
Number of subjects: 1500
Study 26794168 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health insurance
Number of subjects: 1500
Study 25811824 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR (interactive voice recognition calls)
Number of subjects: 21752
Study 25811824 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR+ (interactive voice recognition calls plus additional support)
Number of subjects: 21752
Study 25811824 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR+
Number of subjects: 21752
Study 25811824 — intervention group
Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 21752
Study 22339238 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose (SMBG) intervention
Number of subjects: 375
Study 19136164 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of intravenous magnesium sulfate
Number of subjects: 117
Study 19136164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 19298023 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxinium (OX) femoral heads
Number of subjects: 100
Study 19298023 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chrome (CC) femoral heads
Number of subjects: 100
Study 15778240 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg/6 weeks)
Number of subjects: 82
Study 15778240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 82
Study 12027982 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion
Number of subjects: 145
Study 12027982 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (ANH and ICS)
Number of subjects: 145
Study 10720121 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham feeding in healthy volunteers
Number of subjects: 8
Study 10720121 — intervention group
Group type: COMPARATOR
Intervention: Sham feeding in ACP patients
Number of subjects: 8
Study 9028511 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 micrograms of inhaled beclomethasone dipropionate
Number of subjects: 8
Study 9028511 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of oral prednisone
Number of subjects: 8
Study 9028511 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 8
Study 9028511 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 8
Study 9028511 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of inhaled beclomethasone dipropionate
Number of subjects: 8
Study 9028511 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of oral prednisone
Number of subjects: 8
Study 9028511 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral prednisone
Number of subjects: 8
Study 1900480 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d of RU486 for 4 days from the date of ovulation
Number of subjects: 16
Study 1900480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6872419 — intervention group
Group type: EXPERIMENTAL
Intervention: Metkephamid 140 mg
Number of subjects: 59
Study 6872419 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 100 mg
Number of subjects: 59
Study 6872419 — intervention group
Group type: COMPARATOR
Intervention: Metkephamid 70 mg
Number of subjects: 59
Study 6872419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31634646 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation
Number of subjects: 214
Study 31634646 — intervention group
Group type: EXPERIMENTAL
Intervention: History of pneumonia
Number of subjects: 214
Study 31634646 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux disease
Number of subjects: 214
Study 30241426 — intervention group
Group type: COMPARATOR
Intervention: Very Low-Calorie Ketogenic (VLCK) diet
Number of subjects: 20
Study 27799650 — intervention group
Group type: EXPERIMENTAL
Intervention: mRDTs and ACTs
Number of subjects: 0
Study 27799650 — intervention group
Group type: COMPARATOR
Intervention: Presumptive diagnosis for malaria based on clinical symptoms (Control)
Number of subjects: 0
Study 24356952 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (300,000 IU single oral bolus)
Number of subjects: 30
Study 24356952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21900625 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic medial retinaculum plication (MRP)
Number of subjects: 60
Study 21900625 — intervention group
Group type: COMPARATOR
Intervention: Open vastus medialis plasty (VMP)
Number of subjects: 60
Study 20072066 — intervention group
Group type: EXPERIMENTAL
Intervention: Back squat exercise (1 set of 5 repetitions at 85% 1RM) with recovery durations of 5, 10, 15, or 20 minutes
Number of subjects: 12
Study 20072066 — intervention group
Group type: COMPARATOR
Intervention: Control session (baseline measures on a 30‐second Wingate Test)
Number of subjects: 12
Study 18025884 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate plus calcium/vitamin D
Number of subjects: 82
Study 18025884 — intervention group
Group type: COMPARATOR
Intervention: Calcium/vitamin D alone
Number of subjects: 82
Study 16216756 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 20
Study 16216756 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 20
Study 16216756 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (including crossover results)
Number of subjects: 20
Study 16216756 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (including crossover results)
Number of subjects: 20
Study 16216756 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of verapamil and amiodarone
Number of subjects: 20
Study 16216756 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and/or Amiodarone (long-term follow-up)
Number of subjects: 20
Study 16216756 — intervention group
Group type: COMPARATOR
Intervention: Patients without IRAF (long-term follow-up)
Number of subjects: 20
Study 12120714 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC with horizontal increments and indirect/direct light curing (Group I)
Number of subjects: 40
Study 12120714 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC with diagonal increments and indirect/direct light curing (Group II)
Number of subjects: 40
Study 12120714 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC with diagonal increments and indirect/direct light curing using a transparent matrix (Group III)
Number of subjects: 40
Study 12120714 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC with diagonal increments and indirect/direct light curing with a separating liner (Group IV)
Number of subjects: 40
Study 12120714 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed sandwich restoration (Group V)
Number of subjects: 40
Study 12120714 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC at cervical margins
Number of subjects: 40
Study 10426837 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol alone
Number of subjects: 29
Study 10426837 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol combined with amlodipine
Number of subjects: 29
Study 8435244 — intervention group
Group type: COMPARATOR
Intervention: AAI pacing
Number of subjects: 30
Study 8435244 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 30
Study 3299130 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating treatment tables
Number of subjects: 15
Study 3299130 — intervention group
Group type: COMPARATOR
Intervention: Control (nonrotated)
Number of subjects: 15
Study 28635532 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-15 somatic symptom severity subscale
Number of subjects: 495
Study 27230565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking with Kids - Colorado; experiential classroom-based cooking and tasting curriculum
Number of subjects: 1584
Study 27230565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafeteria Connections; cafeteria-based reinforcements of classroom food experiences using behavioral economic strategies
Number of subjects: 1584
Study 27230565 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARK active recess; playground intervention to engage children in moderate to vigorous activity
Number of subjects: 1584
Study 27230565 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuel for Fun Family; multi-element supports targeting parents to reinforce school-based components at home
Number of subjects: 1584
Study 27230565 — intervention group
Group type: EXPERIMENTAL
Intervention: About Eating; online interactive program for parents addressing constructs of eating competence and food resource management
Number of subjects: 1584
Study 27230565 — intervention group
Group type: EXPERIMENTAL
Intervention: School-level data
Number of subjects: 1584
Study 27230565 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth diet and accelerometry assessments with a subsample of parent-child dyads
Number of subjects: 1584
Study 24828537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mmol/kg Gd‐BOPTA
Number of subjects: 34
Study 24828537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mmol/kg Gd‐BOPTA
Number of subjects: 34
Study 24828537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 mmol/kg Gd‐BOPTA
Number of subjects: 34
Study 24828537 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging at 5 min
Number of subjects: 34
Study 24828537 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging at 10 min with 0.10 mmol/kg Gd‐BOPTA
Number of subjects: 34
Study 22555795 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 40
Study 22555795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21029816 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer for primary PCI
Number of subjects: 3602
Study 21029816 — intervention group
Group type: COMPARATOR
Intervention: Direct admission to PCI center
Number of subjects: 3602
Study 21029816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602
Study 21029816 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitor
Number of subjects: 3602
Study 18576289 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised home-based quadriceps strengthening
Number of subjects: 107
Study 18576289 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 107
Study 16076708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal stimulation (CI + contralateral HA)
Number of subjects: 12
Study 16076708 — intervention group
Group type: COMPARATOR
Intervention: CI alone
Number of subjects: 12
Study 16076708 — intervention group
Group type: COMPARATOR
Intervention: Best-aided condition preoperatively
Number of subjects: 12
Study 11839994 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm environment (35 degrees C, 45% relative humidity)
Number of subjects: 30
Study 11839994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool environment (18 degrees C, 65% relative humidity)
Number of subjects: 30
Study 11839994 — intervention group
Group type: COMPARATOR
Intervention: CABG group in warm environment
Number of subjects: 30
Study 11839994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups in warm and cool environments
Number of subjects: 30
Study 9880280 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxaemia (defined as arterial oxygen saturation <90%)
Number of subjects: 1072
Study 9880280 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical predictors of hypoxaemia
Number of subjects: 1072
Study 9880280 — intervention group
Group type: COMPARATOR
Intervention: Presence of malaria parasitaemia
Number of subjects: 1072
Study 8886214 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprelan 1,000 mg once daily
Number of subjects: 348
Study 8886214 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprosyn 500 mg BID
Number of subjects: 348
Study 8886214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 1858084 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F 104353‐Z2
Number of subjects: 8
Study 1858084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6306179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibromodulcitol (DBD) during radiotherapy, continued with DBD
Number of subjects: 91
Study 6306179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibromodulcitol (DBD) during radiotherapy followed by combination chemotherapy of CCNU and DBD
Number of subjects: 91
Study 6306179 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 91
Study 31222379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) for 15 minutes at 15 °C
Number of subjects: 11
Study 31222379 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (Control)
Number of subjects: 11
Study 31222379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 11
Study 28241037 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisacodyl plus 2 L PEG‐ELP (group B)
Number of subjects: 700
Study 28241037 — intervention group
Group type: COMPARATOR
Intervention: 2 L PEG‐ELP (group A)
Number of subjects: 700
Study 28241037 — intervention group
Group type: COMPARATOR
Intervention: 2 L PEG‐ELP (group C)
Number of subjects: 700
Study 26420134 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Number of subjects: 6000
Study 26420134 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 6000
Study 24128821 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS) at 100-800 μg titrated doses
Number of subjects: 401
Study 22656865 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CR) 25x2 Gy/5 weeks plus sequential boost 8x2 Gy/2 weeks (cumulative dose 66 Gy/7 weeks)
Number of subjects: 70
Study 22656865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated Tomotherapy (TT) 15x2.8 Gy/3 weeks (cumulative dose 51 Gy/3 weeks)
Number of subjects: 70
Study 22656865 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CR)
Number of subjects: 70
Study 22656865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated Tomotherapy (TT)
Number of subjects: 70
Study 19092004 — intervention group
Group type: EXPERIMENTAL
Intervention: St Georg Sled UKR
Number of subjects: 102
Study 19092004 — intervention group
Group type: COMPARATOR
Intervention: Kinematic modular total knee replacement (TKR)
Number of subjects: 102
Study 17298932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of STI
Number of subjects: 464
Study 17298932 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for an STI
Number of subjects: 464
Study 15604915 — intervention group
Group type: EXPERIMENTAL
Intervention: MM (100% AM and 20% FM)
Number of subjects: 70
Study 15604915 — intervention group
Group type: EXPERIMENTAL
Intervention: AM2
Number of subjects: 70
Study 15604915 — intervention group
Group type: COMPARATOR
Intervention: AM
Number of subjects: 70
Study 15604915 — intervention group
Group type: COMPARATOR
Intervention: FM
Number of subjects: 70
Study 15604915 — intervention group
Group type: EXPERIMENTAL
Intervention: MM and AM2
Number of subjects: 70
Study 15604915 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall responses
Number of subjects: 70
Study 11289051 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg once daily
Number of subjects: 54
Study 11289051 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg retard twice daily
Number of subjects: 54
Study 11289051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11289051 — intervention group
Group type: COMPARATOR
Intervention: All groups (Enalapril, Nifedipine, Placebo)
Number of subjects: 54
Study 11289051 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 54
Study 11289051 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 54
Study 11289051 — intervention group
Group type: COMPARATOR
Intervention: Baseline AER
Number of subjects: 54
Study 9647874 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Number of subjects: 377
Study 9647874 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 377
Study 9647874 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 377
Study 9647874 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 377
Study 7847107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclo‐Progynova, containing 0.5 mg of norgestrel
Number of subjects: 20